Dr. Pol Boudes to leave CymaBay Therapeutics — 4 insights

Clinical-stage biopharmaceutical company CymaBay Therapeutics will lose its CMO Pol Boudes, MD, who is leaving the company on his own accord.

Advertisement

What you should know:

1. Dr. Boudes will resign Sept. 30.

2. CymaBay began searching for his replacement.

3. Gideon Hirschfield, MD, will provide medical and clinical support while the company searches for a fulltime replacement.

4. CymaBay is developing treatments for liver and other chronic diseases.

More articles on surgery center:
ASC supply chain tip of the day: Rely on data
Prevent cross contamination with single sterile IV start kits
Medline to Expand Southeast Distribution with New North Carolina Center

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Unlocking Structural Heart Capacity: How Leading Programs Use EMR and Data to Improve Patient Flow and Throughput

Wednesday, August 19
11:00 AM - 12:00 PM CDT

Presenters: Katie Kennedy, MSN, APRN, NP-C, Community Heart and VascularMisty Theriot, BSN, RN, CPHQ, FACC, Lake Charles Memorial Health SystemKatie Worthington, DNP, RN, Atlantic Health SystemTaryn Shipley, MBA, CSSBB, Lean HealthTech

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.